Indication

In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis

Medicine details

Medicine name:
olopatadine hydrochloride and mometasone furoate monohydrate (Ryaltris)
SMC ID:
SMC2418
Pharmaceutical company
Glenmark Pharmaceuticals Europe Ltd
BNF chapter
Ear, nose and oropharynx
Submission type
Abbreviated
Publication due date:
13 December 2021